Abstract:Platinum-based drugs such as cisplatin are widely used in combination chemotherapy for non-small cell lung cancer (NSCLC) owing to their high clinical response rate; however, acquired resistance to cisplatin is eventually inevitable. Circular RNAs (circRNAs) are involved in the development of diverse types of cancers, but their connection to cisplatin-resistance in NSCLC has not been studied. In the present study, two cisplatin-resistant NSCLC cell lines (A549/DDP and PC9/DDP) were established by gradually increasing concentrations of cisplatin in the media. The resulting cell lines possessed high resistance to cisplatin and strong proliferation, migration, and colony formation abilities compared to the parental cells. Microarray analysis identified 19,161 circRNAs that were dysregulated in cisplatin-resistant cell lines (fold change abs>2), including 11,915 up-regulated and 7246 down-regulated circRNAs. The expression of the top five up-regulated and down-regulated circRNAs was validated using real-time quantitative polymerase chain reaction. A circRNA-micro RNA (miRNA) network of the top 20 dysregulated circRNAs and their predicted miRNAs was constructed using Cytoscape. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed that the host genes of the identified circRNAs were involved in the regulation of MAP kinase kinase kinase kinase activity, 6-phosphofructo-2-kinase activity, focal adhesion, ErbB signaling, and ECM-receptor interactions, which may contribute to cisplatin resistance in NSCLC. In summary, this is the first report on circRNA profiling in cisplatin-resistant NSCLC cells and it provides new potential targets for the reversal of cisplatin resistance in NSCLC.

Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies

Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma

Recent Advances in the Contribution of Noncoding RNAs to Cisplatin Resistance in Cervical Cancer

Mir-340 Reverses Cisplatin Resistance Of Hepatocellular Carcinoma Cell Lines By Targeting Nrf2-Dependent Antioxidant Pathway

Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma

Non-coding RNA in Drug Resistance of Hepatocellular Carcinoma

Nanodrugs based on co-delivery strategies to combat cisplatin resistance

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers

Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Self-enforcing HMGB1/NF-κB/HIF-1α Feedback Loop Promotes Cisplatin Resistance in Hepatocellular Carcinoma Cells

Comprehensive Analysis of Circular RNA Expression Profiles in Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines

Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects

Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer

Nanoparticles (NPs)-mediated lncMALAT1 silencing to reverse cisplatin resistance for effective hepatocellular carcinoma therapy

A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery